|
Vaxcyte, Inc. (PCVX) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Vaxcyte, Inc. (PCVX) Bundle
Möchten Sie Vaxcyte, Inc.s innerer Wert beurteilen? Unser (PCVX) DCF-Taschenrechner integriert reale Daten mit umfangreichen Anpassungsfunktionen, sodass Sie Prognosen anpassen und Ihre Anlagestrategien verbessern können.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -87.8 | -98.3 | -214.3 | -464.9 | -569.5 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 1.4 | 1.8 | 9.2 | 3.2 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -89.2 | -100.1 | -223.5 | -468.0 | -569.5 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 386.2 | 246.0 | 931.4 | 1,080.2 | 1,747.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | -.3 | -1.2 | -1.0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 29.8 | 6.8 | 9.8 | 14.6 | 48.5 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -1.2 | -6.6 | -5.8 | -67.9 | -22.4 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -87.8 | -100.1 | -239.6 | -468.0 | -569.5 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -57.5 | -127.0 | -233.5 | -529.0 | -558.1 | -48.5 | .0 | .0 | .0 | .0 |
| WACC, % | 8.63 | 8.63 | 8.63 | 8.63 | 8.63 | 8.63 | 8.63 | 8.63 | 8.63 | 8.63 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -44.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -45 | |||||||||
| Net Debt | -317 | |||||||||
| Equity Value | 272 | |||||||||
| Diluted Shares Outstanding, MM | 122 | |||||||||
| Equity Value Per Share | 2.23 |
What You Will Get
- Editable Forecast Inputs: Effortlessly modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Vaxcyte, Inc. (PCVX) financial data pre-loaded to enhance your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically for you.
- Customizable and Professional: A sleek Excel model that adjusts to your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and optimizing efficiency.
Key Features
- Real-Life PCVX Data: Pre-filled with Vaxcyte’s historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Vaxcyte, Inc. (PCVX) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Vaxcyte, Inc.'s (PCVX) intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Vaxcyte, Inc. (PCVX)?
- Accurate Data: Up-to-date Vaxcyte financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Built-in calculations save you from starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and dependable valuation models for investment analysis in Vaxcyte, Inc. (PCVX).
- Biotech Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Vaxcyte, Inc. (PCVX).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Pharmaceutical Enthusiasts: Gain insights into how biotech companies like Vaxcyte, Inc. (PCVX) are valued in the market.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring intricate valuation calculations.
- Real-World Data: Vaxcyte, Inc.'s (PCVX) historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Visualizations and tables for clear, actionable results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.